Bristol Myers Squibb (CELG-RI) Accumulated Expenses (2009 - 2019)

Bristol Myers Squibb (CELG-RI) has reported Accumulated Expenses for 11 consecutive years, with $5.9 billion the latest figure, recorded in Q1 2019.

• In Q1 2019, Accumulated Expenses rose 5.3% year-over-year to $5.9 billion; the TTM figure through Mar 2019 stood at $5.9 billion (up 5.3% YoY), while the FY2018 annual figure was $6.5 billion, up 7.9% from the prior year.
• Accumulated Expenses declined to $5.9 billion in Q1 2019 per CELG-RI's latest filing, from $6.5 billion in the prior quarter.
• Across five years, Accumulated Expenses topped out at $6.5 billion in Q4 2018 and bottomed at $1.8 billion in Q1 2015.
• Historically, Accumulated Expenses has averaged $4.8 billion across 5 years, with a median of $5.1 billion in 2017.
• Annual changes were most pronounced in 2015 — Accumulated Expenses slipped 10.32% — and 2016, when it surged 140.7%.
• Bristol Myers Squibb's Accumulated Expenses stood at $4.7 billion in 2015, then grew by 11.25% to $5.3 billion in 2016, then grew by 14.1% to $6.0 billion in 2017, then advanced by 7.9% to $6.5 billion in 2018, then retreated by 9.75% to $5.9 billion in 2019.
• Business Quant data shows CELG-RI's Accumulated Expenses at $5.9 billion in Q1 2019, $6.5 billion in Q4 2018, and $5.9 billion in Q3 2018.